Regeneron Pharmaceuticals, Inc. recently signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex, to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods.
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions.
The state-of-the-art complex will consolidate Regeneron’s 440 Tarrytown-based employees, currently scattered among six buildings, into a three-building, interconnected campus. The new facilities will include approximately 194,000 square feet of laboratory and office space in two buildings to be constructed by BioMed Realty Trust over the next two years.
The Company will also retain its 27,000 square foot specialized VelociGene research facility in an existing building at the Landmark at Eastview. The new buildings will incorporate energy efficient technologies along with an open and flexible design that will enhance workplace interactions.
“The generous incentives we have received from New York State, the Town of Greenburgh, and the Westchester County IDA allow us to remain in our current location in Westchester County, ” said Leonard S. Schleifer, M.D., Ph.D., president and CEO of Regeneron. “Further, the new facility will incorporate efficient design features and technologies that will enhance our business operations and provide cost-efficiencies.”
For MORE NEWS BRIEFS, click here.
For a FREE SUBSCRIPTION to Expansion Management, click here.
Go to STATE SPOTLIGHTS to read more about other news and articles about this state.
Go to INDUSTRY SPOTLIGHTS to read more about other news and articles about this industry sector.
Go to INTERNATIONAL SPOTLIGHTS to read more about other news and articles about international expansions.
Means the article is accessible only to our magazine subscribers.
